Friday, Nov. 20, 2015, 93 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $23.06 to $5,010,000.00.

Highlighted Stocks Traded by Insiders:

NxStage Medical (NXTM) - FREE Research Report

Moore Craig W, who is Director at NxStage Medical, sold 1,000 shares at $20.00 on Nov. 20, 2015. Following this transaction, the Director owned 92,046 shares meaning that the stake was reduced by 1.07% with the 1,000-share transaction.

Turk Joseph E Jr, who is President at NxStage Medical, sold 2,000 shares at $19.65 on Nov. 20, 2015. Following this transaction, the President owned 104,463 shares meaning that the stake was reduced by 1.88% with the 2,000-share transaction.

The shares most recently traded at $19.59, down $0.06, or 0.31% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 13,973
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 23,733
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 45,328

The average volume for NxStage Medical has been 569,300 shares per day over the past 30 days. NxStage Medical has a market cap of $1.2 billion and is part of the health care sector and health services industry. Shares are up 8.76% year-to-date as of the close of trading on Friday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 4 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings

rates NxStage Medical as a

hold

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full

NxStage Medical Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Washington Trust Bancorp (WASH) - FREE Research Report

Devault David V, who is Vice Chair, Secretary and CFO at Washington Trust Bancorp, sold 2,183 shares at $41.02 on Nov. 20, 2015. Following this transaction, the Vice Chair, Secretary and CFO owned 40,198 shares meaning that the stake was reduced by 5.15% with the 2,183-share transaction.

The shares most recently traded at $40.90, down $0.12, or 0.29% since the insider transaction. Historical insider transactions for Washington Trust Bancorp go as follows:

  • 4-Week # shares bought: 150
  • 4-Week # shares sold: 4,359
  • 12-Week # shares bought: 150
  • 12-Week # shares sold: 4,959
  • 24-Week # shares bought: 150
  • 24-Week # shares sold: 17,534

The average volume for Washington Trust Bancorp has been 36,000 shares per day over the past 30 days. Washington Trust Bancorp has a market cap of $686.7 million and is part of the financial sector and banking industry. Shares are up 1.72% year-to-date as of the close of trading on Friday.

Washington Trust Bancorp, Inc. operates as the holding company for The Washington Trust Company that offers various banking and financial products and services to individuals and businesses. The company operates in two segments, Commercial Banking and Wealth Management Services. The stock currently has a dividend yield of 3.37%. The company has a P/E ratio of 15.7. Currently, there are no analysts who rate Washington Trust Bancorp a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on WASH - FREE

TheStreet Quant Ratings

rates Washington Trust Bancorp as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, notable return on equity and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Washington Trust Bancorp Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pinnacle West Capital (PNW) - FREE Research Report

Schiavoni Mark A., who is Shareholder at Pinnacle West Capital, sold 4,339 shares at $61.70 on Nov. 20, 2015. Following this transaction, the Shareholder owned 21,705 shares meaning that the stake was reduced by 16.66% with the 4,339-share transaction.

The shares most recently traded at $63.38, up $1.68, or 2.65% since the insider transaction. Historical insider transactions for Pinnacle West Capital go as follows:

  • 4-Week # shares sold: 4,195
  • 12-Week # shares sold: 4,195
  • 24-Week # shares sold: 4,195

The average volume for Pinnacle West Capital has been 966,800 shares per day over the past 30 days. Pinnacle West Capital has a market cap of $7.0 billion and is part of the utilities sector and utilities industry. Shares are down 7.28% year-to-date as of the close of trading on Friday.

Pinnacle West Capital Corporation, through its subsidiary, Arizona Public Service Company, provides retail and wholesale electric services primarily in the State of Arizona. It generates, transmits, and distributes electricity using coal, nuclear, gas, oil, and solar resources. The stock currently has a dividend yield of 3.98%. The company has a P/E ratio of 17.5. Currently, there is 1 analyst who rates Pinnacle West Capital a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PNW - FREE

TheStreet Quant Ratings

rates Pinnacle West Capital as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, good cash flow from operations, increase in net income and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Pinnacle West Capital Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.